TBI‑001: A TRIB2‑Targeted Strategy to Counter Lineage Plasticity and Treatment‑Emergent Neuroendocrine Prostate Cancer

/in /by

A new experimental drug called TBI‑001 targets a protein called TRIB2 in advanced prostate cancer that has become resistant to hormone therapy and starts acquiring neuroendocrine features. This is particularly relevant for treatment‑emergent neuroendocrine prostate cancer (t‑NEPC), a lethal subtype that arises after long‑term androgen‑receptor–targeted therapy, loses dependence on AR signaling, and adopts a neuroendocrine […]

Read more

A First‑in‑Class Dual AR‑V7/AR Molecular Glue Degrader for Metastatic Castration‑Resistant Prostate Cancer

/in /by

Most prostate cancer treatments today target the part of the AR protein that binds hormones, known as the ligand‑binding domain or LBD. At first these drugs like enzalutamide and abiraterone can shrink tumors or slow progression, but over time the cancer adapts and becomes resistant. This adaptation is a major reason why men with mCRPC […]

Read more

Ferroptosis-Nanoparticles Turn Prostate Tumors Hot: Docetaxel + Light Wakes Immunity

/in , /by

Cancer drugs like docetaxel work against prostate, lung, and other cancers, but they hit the whole body and often do not fully wake up the immune system. In this study, the research team built tiny nanoparticles (about 100–120 nm across) that carry docetaxel plus a light‑activated dye (IR808) and are made to open mainly inside […]

Read more

SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision

/in , /by

Researchers at Duke University have developed a new ultrasound‑based method called SonoPIN (“Sonoporation‑assisted Precise Intracellular Nanodelivery”) that helps large anticancer molecules get inside tumor cells with high precision, while causing minimal damage to healthy tissue. In early lab experiments, the technique killed about half of the targeted cancer cells, while more than 99% of non‑targeted […]

Read more

A New CAR‑T Strategy for Bone Cancer That May Help Metastatic Prostate Disease

/in , /by

Scientists have developed a promising new CAR‑T cell therapy for osteosarcoma, the most common bone cancer in children, adolescents, and young adults, and the work carries a cautiously optimistic signal for other solid tumors, including metastatic prostate cancer. In a preclinical study, researchers at Case Western Reserve University and University Hospitals engineered T cells to […]

Read more

Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

/in /by

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]

Read more

Amino Acid Mix Supercharges Lipid Nanoparticle Delivery for mRNA and CRISPR Therapies

/in , /by

Scientists have discovered that a simple mix of three amino acids can greatly improve how well lipid‑nanoparticle (LNP)–based therapies work in the body. These LNPs are tiny fat‑like packages used to carry mRNA or CRISPR components into cells, and they are already at the heart of new vaccines and gene‑editing treatments. The new finding suggests […]

Read more

pre|CISION Platform Update: AVA6103 Outperforms Leading ADC, Phase 1 Dosing Imminent

/in , /by

Since October 2025, when the pre|CISION platform first demonstrated its potential to deliver dual payloads like MMAE and exatecan from a single molecule in prostate cancer models, significant new data has emerged that strengthens its case as a next-generation targeted therapy. The platform’s ability to exploit fibroblast activation protein (FAP) in the tumor microenvironment for […]

Read more

Evolutionary Oncology: A New Research Validates This Approach in Preclinical Models

/in , /by

Researchers at Trinity College Dublin and Moffitt Cancer Center have uncovered a promising prostate cancer breakthrough: radiation-resistant tumor cells become unexpectedly vulnerable to attack by natural killer (NK) immune cells, presenting a strategic “evolutionary double-bind” that could transform treatment approaches. This discovery challenges traditional views of therapy resistance, showing that when prostate cancer cells adapt […]

Read more

Ultrasound Nanobubbles Crack Prostate Cancer’s Collagen Fortress Improving Immunotherapy Penetration

/in , , /by

Researchers at Case Western Reserve University used tiny ultrasound-activated nanobubbles to dismantle the tough collagen walls that shield solid tumors from treatments. These “fortresses” made of stiff, crosslinked collagen block immune cells and drugs from reaching cancer cells deep inside, a major hurdle in fighting aggressive tumors like prostate cancer. The nanobubbles, filled with inert […]

Read more